Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.58 |
| ▸ | ADH1C | P00326 | 1/20 | 0.58 |
| ▸ | ADH1A | P07327 | 1/20 | 0.58 |
| ▸ | ADH4 | P08319 | 1/20 | 0.58 |
| ▸ | ADH7 | P40394 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | DNM1 | Q05193 | 2/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.39 |
| ▸ | FDPS | P14324 | 3/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726335 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL3689236 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL277214 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4603730 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL1203435 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL4660468 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL570864 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL14142731 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL16223598 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL2237108 | 1.00 | ADH1B (0.58) | ADH1BADH1CADH1AADH4ADH7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240175005-A1 | PURIFICATION AND RECYCLING OF mRNA NUCLEOTIDE CAPS | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-30 | — | — | US | claimed |
| EP-4314284-A1 | PURIFICATION AND RECYCLING OF MRNA NUCLEOTIDE CAPS | Modernatx, Inc. (US) | 2024-02-07 | — | — | EP | claimed |
| WO-2022212710-A1 | PURIFICATION AND RECYCLING OF mRNA NUCLEOTIDE CAPS | MODERNATX, INC. (US) | 2022-10-06 | — | — | WO | claimed |
| EP-3165561-B1 | RAPID CURING THIOL EPOXY RESIN WITH IMPROVED COMPRESSION STRENGTH PERFORMANCE | BOEING CO (US) | 2021-01-13 | — | — | EP | claimed |
| CN-110669058-A | Tricyclic quinolone carboxylic acid and preparation method thereof | 江西农业大学 | 2020-01-10 | — | — | CN | claimed |
| EP-2980093-B1 | BIS(6-METHYL-3-SULPHOPHENYL)(2-METHYLPHENYL)PHOSPHINE, AMMONIUM SALT THEREOF, AND METHOD FOR PRODUCING SAME | KURARAY CO (JP) | 2019-01-09 | — | — | EP | claimed |
| EP-2980092-B1 | BIS(6-METHYL-3-SULPHOPHENYL)PHENYLPHOSPHINE, AMMONIUM SALT THEREOF, AND METHOD FOR PRODUCING SAME | KURARAY CO (JP) | 2017-10-04 | — | — | EP | claimed |
| EP-1886704-B1 | ADSORBENT AND COLUMN FOR EXTRACORPOREAL CIRCULATION | TORAY INDUSTRIES (JP) | 2016-09-28 | — | — | EP | claimed |
| EP-1669383-B1 | CATALYST COMPOSITION FOR PRODUCTION OF RIGID POLYURETHANE FOAM AND ISOCYANURATE-MODIFIED RIGID POLYURETHANE FOAM AND RAW-MATERIAL COMPOSITION CONTAINING THE SAME | TOSOH CORP (JP) | 2014-11-12 | — | — | EP | claimed |
| WO-2006037461-A2 | METHOD FOR ISOLATING AND SEPARATING CARBOHYDRATES FROM AQUEOUS MEDIA | UNIVERSITÄT ROSTOCK (DE) | 2006-04-13 | — | — | WO | claimed |
| EP-1171222-B1 | PROCESS FOR REMOVING HYDROGEN SULFIDE FROM GASES | CRYSTATECH INC (US) | 2004-09-01 | — | — | EP | claimed |
| US-20260109965-A1 | PURIFICATION OF NUCLEOTIDES BY MEANS OF A MIXED-MODE PURIFICATION SYSTEM | MODERNATX INC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4357382-B1 | IONICALLY MODIFIED POLYISOCYANATE MIXTURE | COVESTRO DEUTSCHLAND AG (DE) | 2025-07-23 | — | — | EP | disclosed |
| US-20240383940-A1 | SYNTHESIS OF TRINUCLEOTIDE AND TETRANUCLEOTIDE CAPS FOR MRNA PRODUCTION | Moderna TX, Inc. (US) | 2024-11-21 | — | — | US | disclosed |
| US-20240175005-A1 | PURIFICATION AND RECYCLING OF mRNA NUCLEOTIDE CAPS | ARES CAPITAL CORPORATION, AS AGENT | 2024-05-30 | — | — | US | disclosed |
| US-6159379-A | Organic ammonium salts for the removal of water soluble organics in produced water | BAKER HUGHES INCORPORATED (US) | 2000-12-12 | — | — | US | disclosed |
| EP-0940408-A1 | Metalorganic compounds | Bayer Aktiengesellschaft (DE) | 1999-09-08 | — | — | EP | disclosed |
| EP-0940412-A1 | Atactic propylene (co)polymers | Bayer Aktiengesellschaft (DE) | 1999-09-08 | — | — | EP | disclosed |
| EP-0671427-B1 | Heat-curable epoxy resin composition having good reactivity/stability behaviour | CIBA GEIGY AG (CH) | 1998-05-27 | — | — | EP | disclosed |
| EP-0671427-A1 | Heat-curable epoxy resin composition having good reactivity/stability behaviour | CIBA-GEIGY AG (CH) | 1995-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109965-A1 | PURIFICATION OF NUCLEOTIDES BY MEANS OF A MIXED-MODE PURIFICATION SYSTEM | RNMT, NSUN2, NSUN3 | ADH1B 3759/4885ADH1C 3982/4885ADH1A 3998/4885 |
| US-20240383940-A1 | SYNTHESIS OF TRINUCLEOTIDE AND TETRANUCLEOTIDE CAPS FOR MRNA PRODUCTION | RNGTT, RNMT, UPF1 | ADH1B 3681/4885ADH1C 3638/4885ADH1A 3906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.